Journal Mobile Options
Table of Contents
Vol. 3, No. 5, 2009
Issue release date: December 2009
Sex Dev 2009;3:237–244

Functional Analysis of Novel Androgen Receptor Mutations in a Unique Cohort of Indonesian Patients with a Disorder of Sex Development

Elfferich P. · Juniarto A.Z. · Dubbink H.J. · van Royen M.E. · Molier M. · Hoogerbrugge J. · Houtsmuller A.B. · Trapman J. · Santosa A. · de Jong F.H. · Drop S.L.S. · Faradz S.M.H. · Brüggenwirth H. · Brinkmann A.O.
Departments of aClinical Genetics, bPathology, cReproduction and Development, dInternal Medicine and ePediatric Endocrinology, Sophia Children’s Hospital, Erasmus MC, Rotterdam, The Netherlands; fDivision of Human Genetics, Center for Biomedical Research and gDepartment of Urology, Faculty of Medicine, Diponegoro University, Dr. Kariadi Hospital, Semarang, Indonesia

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Mutations in the androgen receptor (AR) gene, rendering the AR protein partially or completely inactive, cause androgen insensitivity syndrome, which is a form of a 46,XY disorder of sex development (DSD). We present 3 novel AR variants found in a cohort of Indonesian DSD patients: p.I603N, p.P671S, and p.Q738R. The aim of this study was to determine the possible pathogenic nature of these newly found unclassified variants. To investigate the effect of these variants on AR function, we studied their impact on transcription activation, AR ligand-binding domain interaction with an FxxLF motif containing peptide, AR subcellular localization, and AR nuclear dynamics and DNA-binding. AR-I603N had completely lost its transcriptional activity due to disturbed DNA-binding capacity and did not show the 114-kDa hyperphosphorylated AR protein band normally detectable after hormone binding. The patient with AR-I603N displays a partial androgen insensitivity syndrome phenotype, which is explained by somatic mosaicism. A strongly reduced transcriptional activity was observed for AR-Q738R, together with diminished interaction with an FxxLF motif containing peptide. AR-P671S also showed reduced transactivation ability, but no change in DNA- or FxxLF-binding capacity and interferes with transcriptional activity for as yet unclear reasons.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Brüggenwirth HT, Boehmer AL, Lobaccaro JM, Chiche L, Sultan C, et al: Substitution of Ala564 in the first zinc cluster of the deoxyribonucleic acid (DNA)-binding domain of the androgen receptor by Asp, Asn, or Leu exerts differential effects on DNA binding. Endocrinology 139:103–110 (1998).
  2. Claessens F, Verrijdt G, Schoenmakers E, Haelens A, Peeters B, et al: Selective DNA binding by the androgen receptor as a mechanism for hormone-specific gene regulation. J Steroid Biochem Mol Biol 76:23–30 (2001).
  3. Dubbink HJ, Hersmus R, Verma CS, van der Korput HA, Berrevoets CA, et al: Distinct recognition modes of FXXLF and LXXLL motifs by the androgen receptor. Mol Endocrinol 18:2132–2150 (2004).
  4. Dubbink HJ, Hersmus R, Pike AC, Molier M, Brinkmann AO, et al: Androgen receptor ligand-binding domain interaction and nuclear receptor specificity of FXXLF and LXXLL motifs as determined by L/F swapping. Mol Endocrinol 20:1742–1755 (2006).
  5. Farla P, Hersmus R, Geverts B, Mari PO, Nigg AL, et al: The androgen receptor ligand-binding domain stabilizes DNA binding in living cells. J Struct Biol 147:50–61 (2004).
  6. Farla P, Hersmus R, Trapman J, Houtsmuller AB: Antiandrogens prevent stable DNA-binding of the androgen receptor. J Cell Sci 118:4187–4198 (2005).
  7. Giwercman YL, Ivarsson SA, Richthoff J, Lundin KB, Giwercman A: A novel mutation in the D-box of the androgen receptor gene (S597R) in two unrelated individuals is associated with both normal phenotype and severe PAIS. Horm Res 61:58–62 (2004).
  8. Gottlieb B, Trifiro M, Lumbroso R, Vasiliou DM, Pinsky L: The androgen receptor gene mutations database. Nucleic Acids Res 24:151–154 (1996).
  9. He B, Kemppainen JA, Wilson EM: FXXLF and WXXLF sequences mediate the NH2-terminal interaction with the ligand binding domain of the androgen receptor. J Biol Chem 275:22986–22994 (2000).
  10. He B, Gampe RT Jr, Kole AJ, Hnat AT, Stanley TB, et al: Structural basis for androgen receptor interdomain and coactivator interactions suggests a transition in nuclear receptor activation function dominance. Mol Cell 16:425–438 (2004).
  11. Hiort O, Sinnecker GH, Holterhus PM, Nitsche EM, Kruse K: The clinical and molecular spectrum of androgen insensitivity syndromes. Am J Med Genet 63:218–222 (1996).
  12. Hiort O, Sinnecker GH, Holterhus PM, Nitsche EM, Kruse K: Inherited and de novo androgen receptor gene mutations: investigation of single-case families. J Pediatr 132:939–943 (1998).
  13. Holterhus PM, Brüggenwirth HT, Hiort O, Kleinkauf-Houcken A, Kruse K, et al: Mosaicism due to a somatic mutation of the androgen receptor gene determines phenotype in androgen insensitivity syndrome. J Clin Endocrinol Metab 82:3584–3589 (1997).
  14. Hughes IA: Disorders of sex development: a new definition and classification. Best Pract Res Clin Endocrinol Metab 22:119–134 (2008).
  15. Hur E, Pfaff SJ, Payne ES, Gron H, Buehrer BM, Fletterick RJ: Recognition and accommodation at the androgen receptor coactivator binding interface. PLoS Biol 2:E274 (2004).
  16. Jenster G, van der Korput HA, van Vroonhoven C, van der Kwast TH, Trapman J, Brinkmann AO: Domains of the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization. Mol Endocrinol 5:1396–1404 (1991).
  17. Jenster G, de Ruiter PE, van der Korput HA, Kuiper GG, Trapman J, Brinkmann AO: Changes in the abundance of androgen receptor isotypes: effects of ligand treatment, glutamine-stretch variation, and mutation of putative phosphorylation sites. Biochemistry 33:14064–14072 (1994).
  18. Kuiper GG, de Ruiter PE, Trapman J, Jenster G, Brinkmann AO: In vitro translation of androgen receptor cRNA results in an activated androgen receptor protein. Biochem J 296:161–167 (1993).
  19. Lubahn DB, Joseph DR, Sar M, Tan J, Higgs HN, et al: The human androgen receptor: complementary deoxyribonucleic acid cloning, sequence analysis and gene expression in prostate. Mol Endocrinol 2:1265–1275 (1988).
  20. Quigley CA, De Bellis A, Marschke KB, el-Awady MK, Wilson EM, French FS: Androgen receptor defects: historical, clinical, and molecular perspectives. Endocr Rev 16:271–321 (1995).
  21. Quigley CA, Tan JA, He B, Zhou ZX, Mebarki F, et al: Partial androgen insensitivity with phenotypic variation caused by androgen receptor mutations that disrupt activation function 2 and the NH(2)- and carboxyl-terminal interaction. Mech Ageing Dev 125:683–695 (2004).
  22. Steketee K, Berrevoets CA, Dubbink HJ, Doesburg P, Hersmus R, et al: Amino acids 3– 13 and amino acids in and flanking the 23FxxLF27 motif modulate the interaction between the N-terminal and ligand-binding domain of the androgen receptor. Eur J Biochem 269:5780–5791 (2002).
  23. Trapman J, Dubbink HJ: The role of cofactors in sex steroid action. Best Pract Res Clin Endocrinol Metab 21:403–414 (2007).
  24. van de Wijngaart DJ, van Royen ME, Hersmus R, Pike AC, Houtsmuller AB, et al: Novel FXXFF and FXXMF motifs in androgen receptor cofactors mediate high affinity and specific interactions with the ligand-binding domain. J Biol Chem 281:19407–19416 (2006).
  25. van Royen ME, Cunha SM, Brink MC, Mattern KA, Nigg AL, et al: Compartmentalization of androgen receptor protein-protein interactions in living cells. J Cell Biol 177:63–72 (2007).
  26. van Royen ME, Farla P, Mattern KA, Geverts B, Trapman J, Houtsmuller AB: Fluorescence recovery after photobleaching (FRAP) to study nuclear protein dynamics in living cells. Methods Mol Biol 464:363–385 (2009).

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50